At the same time, by adding drugs that target vascular endothelial growth factor (VEGF) (such as bevacizumab, ramucirumab, and ziv-aflibercept), and drugs that inhibit the epidermal growth factor receptor (EGFR) signaling pathway (such as cetuximab and panitumumab) significantly improved median survival in patients with metastatic colorectal cancer (Mody and Bekaii-Saab, 2018). This evidence concerns the gene VEGFA and metastatic colorectal cancer.